179 related articles for article (PubMed ID: 17464275)
1. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H; Denardo GL; Denardo SJ
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
[TBL] [Abstract][Full Text] [Related]
2. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
3. Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer.
Winthrop MD; DeNardo SJ; DeNardo GL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3088s-3094s. PubMed ID: 10541348
[TBL] [Abstract][Full Text] [Related]
4. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
Albrecht H; Burke PA; Natarajan A; Xiong CY; Kalicinsky M; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2004; 15(1):16-26. PubMed ID: 14733579
[TBL] [Abstract][Full Text] [Related]
5. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.
Xiong CY; Natarajan A; Shi XB; Denardo GL; Denardo SJ
Protein Eng Des Sel; 2006 Aug; 19(8):359-67. PubMed ID: 16760193
[TBL] [Abstract][Full Text] [Related]
6. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.
DeNardo SJ; DeNardo GL; DeNardo DG; Xiong CY; Shi XB; Winthrop MD; Kroger LA; Carter P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3213s-3218s. PubMed ID: 10541366
[TBL] [Abstract][Full Text] [Related]
7. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
Winthrop MD; DeNardo SJ; Albrecht H; Mirick GR; Kroger LA; Lamborn KR; Venclovas C; Colvin ME; Burke PA; DeNardo GL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3845S-53S. PubMed ID: 14506182
[TBL] [Abstract][Full Text] [Related]
9. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
10. Engineered single chain antibody fragments for radioimmunotherapy.
Huhalov A; Chester KA
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
DeNardo SJ; Richman CM; Albrecht H; Burke PA; Natarajan A; Yuan A; Gregg JP; O'Donnell RT; DeNardo GL
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
[TBL] [Abstract][Full Text] [Related]
13. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
[TBL] [Abstract][Full Text] [Related]
14. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
17. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
18. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey RM; Goldenberg DM
J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping.
Doi M; Yokoyama A; Kondo K; Ohnishi H; Ishikawa N; Hattori N; Kohno N
Cancer Sci; 2006 May; 97(5):420-9. PubMed ID: 16630141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
